Johnson & Johnson Ordered to Pay $8 Billion to Man Who Developed Breasts After Taking Risperdal

It's the latest legal blow for the company

The countdown to Brandweek is on! Join us, Sept. 12-16, to identify new growth opportunities, solve challenges and connect with power players. View the lineup and secure your pass.

It’s shaping up to be an expensive few years for Johnson & Johnson.

AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Subscribe today!

To Read the Full Story Become an Adweek+ Subscriber

View Subscription Options

Already a member? Sign in